Igyxos: Human infertility: Igyxos raises 7.5M € to finance the development of its drug candidate

Igyxos, a biotechnology company specializing in the development of a new treatment for female and male infertility, has announced the success of its € 7.5 million fundraising campaign as part of a Bpifrance Series A , via the Fonds Accélération Biotechnologies Santé managed by Bpifrance as part of the Investments for the Future Program, alongside the Go Capital Amorçage II and Loire Valley Invest funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation.